C-VWDEGordian Biotechnology
in vivo drug discovery, Mosaic Screening, transcriptomics
discoverydiscoveringgene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-VWDE
C-VWDEC-VWDEin vivo drug discovery, Mosaic Screening, transcriptomics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Gordian Biotechnology states that complex diseases of aging need a fundamentally better discovery approach, and that the company has built the first in vivo therapeutic screening platform to radically improve drug development for these conditions. The snapshot also indicates a belief that age-related disease can be addressed by scalable in vivo screening and that gene therapy is an appropriate modality for targeting complex age-related diseases.
SourceGordian Biotechnology states that it is pioneering a novel screening platform intended to radically increase the efficiency of therapeutic development for complex diseases of aging. The company also frames its mission as audacious and emphasizes teamwork and extraordinary talent in bioinformatics, molecular biology, and gene therapy as necessary to achieve it.
SourceGordian Biotechnology presents the view that diseases of aging are complex problems that need a different therapeutic discovery approach, and that a gene-therapy-based discovery platform can radically improve research and development for these conditions. The page also signals a belief that progress in aging therapeutics should be built at the intersection of disease biology, gene therapy, functional genomics, and artificial intelligence, with gene therapy positioned as especially important for targeting age-related complex disease.
Source